RNA Manufacturing Articles

  1. A New Purification Strategy For The Removal Of dsRNA Impurities From IVT mRNA Products 8/10/2026

    NIST research introduces a gentle SEC method that separates dsRNA impurities from IVT mRNA by tweaking buffer pH, achieving 81.8% target recovery without transcript damage.

  2. Bridging The Atlantic: A European Executive's Guide To Building A Successful U.S. RNA Business (Pt. 2) 8/6/2026

    European RNA biotech leaders can accelerate U.S. success by aligning fundraising, partnerships, manufacturing, hiring, and regulatory strategy from day one.

  3. The Delivery Challenge For In Vivo Cell Engineering 7/30/2026

    As RNA therapies expand beyond the liver, delivery—not payload design—has become the defining challenge for precise, scalable in vivo cell engineering.

  4. Building An ASO For TUBB4A-Related Leukodystrophy (Pt. 1) 7/28/2026

    SynaptixBio CEO Dan Williams explains how the company selected an ASO for TUBB4A leukodystrophy by balancing potency, safety, and translational rigor to advance a rare disease therapy.

  5. Nucleic Acid Ligases: Connecting The Pieces For Sustainable And Scalable Production Of Oligonucleotide Therapeutics 7/27/2026

    Chemoenzymatic ligation could overcome the scalability and sustainability limits of traditional oligonucleotide manufacturing, enabling more efficient RNA drug production.

  6. Soliman Says… 5 Questions Every RNA Platform Must Answer Before Investors Write The Check 7/21/2026

    A practical framework for evaluating whether an RNA company has the science, strategy, scalability, and discipline to become a lasting platform.

  7. Building A Self-Driving Lab For LNP Development 7/20/2026

    With commercially available components, MIT researchers built a platform that accelerates LNP process development, optimization, and autonomous manufacturing research.

  8. Beyond Vaccines: Can RNA Sense Gases? 7/20/2026

    Could RNA sense its environment? A new hypothesis explores how RNA may detect temperature and gases, inspiring smarter, adaptive RNA therapeutics.

  9. 5 Critical Regulatory Topics To Watch In The Oligo Sector 7/16/2026

    Though our guidances have helped us achieve upwards of 20 commercially approved oligo products, as I listened to GSK’s director of CMC policy and advocacy, Katie Duncan, present at TIDES, it struck me just how far we have yet to come. Here, I single out a few of the biggest topics of regulatory discussion shaping the oligo therapeutics market.

  10. Beyond Gene Silencing: Harnessing Regulatory RNAs To Increase Gene Expression In Haploinsufficient Disease 7/16/2026

    Can RNA therapeutics increase — not silence — gene expression? Regulatory RNA-targeting ASOs may redefine treatment for haploinsufficient diseases.